202 related articles for article (PubMed ID: 32012484)
1. Stereotactic ablative radiotherapy of 60 Gy in eight fractions is safe for ultracentral non-small cell lung cancer.
Yang D; Cui J; Zhao J; You J; Yu R; Yu H; Jiang L; Li D; Xu B; Shi A
Thorac Cancer; 2020 Mar; 11(3):754-761. PubMed ID: 32012484
[TBL] [Abstract][Full Text] [Related]
2. Long-term outcomes in patients with central and ultracentral non-small cell lung cancer treated with stereotactic body radiotherapy: single-institution experience.
Song X; Zhao L; Jiang N; Ding N; Zong D; Zhang N; Wang D; Wen J; He X; Kong C; Zhu X
Curr Probl Cancer; 2023 Jun; 47(3):100956. PubMed ID: 36966677
[TBL] [Abstract][Full Text] [Related]
3. Ultracentral Tumors Treated With Stereotactic Body Radiotherapy: Single-Institution Experience.
Raman S; Yau V; Pineda S; Le LW; Lau A; Bezjak A; Cho BCJ; Sun A; Hope AJ; Giuliani M
Clin Lung Cancer; 2018 Sep; 19(5):e803-e810. PubMed ID: 30007498
[TBL] [Abstract][Full Text] [Related]
4. Tumor Control and Toxicity after SBRT for Ultracentral, Central, and Paramediastinal Lung Tumors.
Nguyen KNB; Hause DJ; Novak J; Monjazeb AM; Daly ME
Pract Radiat Oncol; 2019 Mar; 9(2):e196-e202. PubMed ID: 30496842
[TBL] [Abstract][Full Text] [Related]
5. Five- Versus Ten-Fraction Regimens of Stereotactic Body Radiation Therapy for Primary and Metastatic NSCLC.
Steber CR; Hughes RT; Soike MH; Jacobson T; Helis CA; Farris JC; Farris MK
Clin Lung Cancer; 2021 Jan; 22(1):e122-e131. PubMed ID: 33046359
[TBL] [Abstract][Full Text] [Related]
6. Ten fraction hypofractionated stereotactic body radiotherapy for the management of ultracentral lung tumors: a retrospective analysis of dosimetry, outcomes, and toxicity.
Rock C; Sood S; Cao Y; Shelton S; Chen RC; Wang F
Radiat Oncol; 2023 Aug; 18(1):128. PubMed ID: 37533092
[TBL] [Abstract][Full Text] [Related]
7. Long term outcome after 48 Gy stereotactic ablative body radiotherapy for peripheral stage I non-small cell lung cancer.
Dubaere E; Goffaux M; Wanet M; Bihin B; Gheldof C; Demoulin AS; Bolly A; Bustin F; Duplaquet F; Baugnee PE; Gustin M; Hers V; Maisin F; Marchand E; Ocak S; Pirard L; Vancutsem O; Van Neck E; Vandermoten G; Zaharia L; Remouchamps V
BMC Cancer; 2019 Jun; 19(1):639. PubMed ID: 31253136
[TBL] [Abstract][Full Text] [Related]
8. Stereotactic ablative radiotherapy (SABR) for treatment of central and ultra-central lung tumors.
Chaudhuri AA; Tang C; Binkley MS; Jin M; Wynne JF; von Eyben R; Hara WY; Trakul N; Loo BW; Diehn M
Lung Cancer; 2015 Jul; 89(1):50-6. PubMed ID: 25997421
[TBL] [Abstract][Full Text] [Related]
9. Long-Term Outcomes of Salvage Stereotactic Ablative Radiotherapy for Isolated Lung Recurrence of Non-Small Cell Lung Cancer: A Phase II Clinical Trial.
Sun B; Brooks ED; Komaki R; Liao Z; Jeter M; McAleer M; Balter PA; Welsh JD; O'Reilly M; Gomez D; Hahn SM; Sepesi B; Rice DC; Heymach JV; Chang JY
J Thorac Oncol; 2017 Jun; 12(6):983-992. PubMed ID: 28259750
[TBL] [Abstract][Full Text] [Related]
10. The safety and effectiveness of stereotactic body radiotherapy for central versus ultracentral lung tumors.
Chang JH; Poon I; Erler D; Zhang L; Cheung P
Radiother Oncol; 2018 Nov; 129(2):277-283. PubMed ID: 30049454
[TBL] [Abstract][Full Text] [Related]
11. Safety and Efficacy of Stereotactic Body Radiotherapy in Ultracentral Lung Tumors Using a Risk-optimized Fractionation Scheme.
Regnery S; Eichkorn T; Weykamp F; Held T; Weusthof K; Dinges LA; El-Shafie RA; Winter H; Thomas M; Debus J; Adeberg S; Hörner-Rieber J
Clin Lung Cancer; 2021 Jul; 22(4):332-340.e3. PubMed ID: 33281061
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of Hypofractionated High-Dose Radiotherapy in Poor-Risk Patients with "Ultracentral" Non-Small Cell Lung Cancer.
Tekatli H; Haasbeek N; Dahele M; De Haan P; Verbakel W; Bongers E; Hashemi S; Nossent E; Spoelstra F; de Langen AJ; Slotman B; Senan S
J Thorac Oncol; 2016 Jul; 11(7):1081-9. PubMed ID: 27013408
[TBL] [Abstract][Full Text] [Related]
13. SUNSET: Stereotactic Radiation for Ultracentral Non-Small-Cell Lung Cancer-A Safety and Efficacy Trial.
Giuliani M; Mathew AS; Bahig H; Bratman SV; Filion E; Glick D; Louie AV; Raman S; Swaminath A; Warner A; Yau V; Palma D
Clin Lung Cancer; 2018 Jul; 19(4):e529-e532. PubMed ID: 29759332
[TBL] [Abstract][Full Text] [Related]
14. Risk-adapted stereotactic ablative radiotherapy for central and ultra-central lung tumours.
Lenglet A; Campeau MP; Mathieu D; Bahig H; Lambert L; Vu T; Roberge D; Bilodeau L; Filion E
Radiother Oncol; 2019 May; 134():178-184. PubMed ID: 31005213
[TBL] [Abstract][Full Text] [Related]
15. Feasible Optimization of Stereotactic Ablative Radiotherapy Dose by Tumor Size for Stage I Non-small-cell Lung Cancer.
Lee S; Song SY; Kim SS; Choi W; Je HU; Back GM; Cho B; Jeong SY; Choi EK
Clin Lung Cancer; 2018 Mar; 19(2):e253-e261. PubMed ID: 29196082
[TBL] [Abstract][Full Text] [Related]
16. Risk-adapted stereotactic body radiation therapy for central and ultra-central early-stage inoperable non-small cell lung cancer.
Meng MB; Wang HH; Zaorsky NG; Sun BS; Zhu L; Song YC; Li FT; Dong Y; Wang JS; Chen HM; Yu XY; Yuan ZY
Cancer Sci; 2019 Nov; 110(11):3553-3564. PubMed ID: 31464032
[TBL] [Abstract][Full Text] [Related]
17. Ablative radiotherapy for ultracentral lung cancers: Dosimetric, geometric, and volumetric predictors of outcomes and toxicity.
Breen WG; Jeans EB; Gergelis KR; Garces YI; Park SS; Merrell KW; Peikert TD; Mansfield AS; Wigle DA; Harmsen WS; Ellerbusch DC; Olivier KR; John Lucido J; Owen D
Radiother Oncol; 2021 May; 158():246-252. PubMed ID: 33711411
[TBL] [Abstract][Full Text] [Related]
18. Long-term Overall Survival Outcomes in Patients with Early Stage, Peripherally Located, Non-small Cell Lung Cancer Treated with Stereotactic Ablative Radiotherapy in a Non-academic Cancer Centre.
Wood A; Aynsley E; Kumar G; Masinghe S; Anderson M; Veeratterapillay J; Huntley C; Blower A; Green J; Johnson D; Daniel J; Curtis H; Reynolds J; Turnbull M; Harland K; Swingler A; Banham E; Burke K; Bradley J; Greenhalgh A; Peedell C
Clin Oncol (R Coll Radiol); 2021 May; 33(5):283-291. PubMed ID: 33341333
[TBL] [Abstract][Full Text] [Related]
19. Stereotactic ablative radiotherapy for ultra-central lung tumors: prioritize target coverage or organs at risk?
Murrell DH; Laba JM; Erickson A; Millman B; Palma DA; Louie AV
Radiat Oncol; 2018 Apr; 13(1):57. PubMed ID: 29606150
[TBL] [Abstract][Full Text] [Related]
20. Toxicity and Efficacy of Stereotactic Ablative Body Radiotherapy for Moderately Central Non-small Cell Lung Cancers Using 50 Gy in Five Fractions.
Rulach R; McLoone P; Lumsden G; McKay S; MacLaren V; Macphee J; Moore K; Omand M; Sproule M; Currie S; Aitken A; Ferguson R; Valentine R; Houston P; Harrow S; Hicks J
Clin Oncol (R Coll Radiol); 2020 Apr; 32(4):250-258. PubMed ID: 31607611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
